文献速递呼吸衰竭与机械通气儿科与产科急症

尼塞韦单抗治疗在儿科急诊中预防呼吸道合胞病毒毛细支气管炎的效果

Nirsevimab Treatment of RSV Bronchiolitis in Pediatric Emergency Departments.
PubMed 文献 · JAMA Netw Open · 2025-10-01
一句话结论在法国实施尼塞韦单抗免疫的第二季,其对儿科急诊呼吸道合胞病毒毛细支气管炎的保护效果为89.3%,与第一季的83.2%相当。

该多中心检测阴性病例对照研究纳入法国5个儿科急诊科在尼塞韦单抗实施的头两个流行季(2023年10月5日至2024年2月29日;2024年10月15日至2025年1月31日)接诊的636例1岁以下首次毛细支气管炎患儿,均接受鼻咽部呼吸道合胞病毒检测。两个流行季中分别有71.1%和71.8%的患儿呼吸道合胞病毒检测阳性。尼塞韦单抗对呼吸道合胞病毒毛细支气管炎的保护效果第一季为83.2%(95%CI 68.0%-91.4%),第二季为89.3%(95%CI 77.8%-95.1%),两季间无统计学显著差异(P = .97)。亚组和敏感性分析结果相似。作者认为,尽管近期发现呼吸道合胞病毒B型耐药株,但迄今似乎未产生重要临床后果,在广泛使用尼塞韦单抗的背景下持续密切监测呼吸道合胞病毒流行病学仍至关重要。

要点

  • 在法国实施尼塞韦单抗免疫的第二季,其对儿科急诊呼吸道合胞病毒毛细支气管炎的保护效果为89.3%(95%CI 77.8%-95.1%)。
  • 第一季的保护效果为83.2%(95%CI 68.0%-91.4%),两季间无统计学显著差异(P = .97)。
  • 两个流行季中尼塞韦单抗免疫覆盖率均为25.5%(162/636),呼吸道合胞病毒检测阳性率分别为71.1%(273/384)和71.8%(181/252)。
  • 尽管近期发现呼吸道合胞病毒B型耐药株,作者认为迄今似乎未产生重要临床后果。
  • 作者认为在广泛使用尼塞韦单抗的背景下持续密切监测呼吸道合胞病毒流行病学仍至关重要。

适用人群与场景

  • 法国5个儿科急诊科接诊的1岁以下、诊断为首次毛细支气管炎发作并接受鼻咽部呼吸道合胞病毒检测的婴儿,研究时段为2023年10月5日至2024年2月29日及2024年10月15日至2025年1月31日。

研究设计与关键结果

  • 研究类型为多中心检测阴性病例对照研究,纳入636例患儿(中位年龄3.0个月,四分位距1.4-5.0个月;男童333例,占52.4%),来自法国5个儿科急诊科。
  • 两个流行季合计162/636例(25.5%)接受了尼塞韦单抗免疫。
  • 第一季384例中273例(71.1%)呼吸道合胞病毒检测阳性;第二季252例中181例(71.8%)阳性。
  • 尼塞韦单抗对呼吸道合胞病毒毛细支气管炎的保护效果第一季为83.2%(95%CI 68.0%-91.4%),第二季为89.3%(95%CI 77.8%-95.1%),两季间无统计学显著差异(P = .97)。
  • 亚组和敏感性分析结果相似。

证据类型、等级与局限

  • 证据类型为多中心检测阴性病例对照研究。
  • 作者指出,尽管近期发现呼吸道合胞病毒B型耐药株,但迄今似乎未产生重要临床后果。
  • 作者认为在广泛使用尼塞韦单抗的背景下持续密切监测呼吸道合胞病毒流行病学仍至关重要。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在法国实施尼塞韦单抗免疫的第二季,其减少儿科急诊呼吸道合胞病毒毛细支气管炎就诊的效果高,与第一季观察到的效果相当。
  • 作者认为,尽管近期发现呼吸道合胞病毒B型耐药株,但迄今似乎未产生重要临床后果。
  • 作者认为,在广泛使用尼塞韦单抗的背景下持续密切监测呼吸道合胞病毒流行病学仍至关重要。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: New resistant mutations of respiratory syncytial virus type B (RSV-B) have been observed during the first year of implementation nirsevimab treatment. During the second season of implementation of nirsevimab treatment in France, RSV-B was predominant.

OBJECTIVES: To assess and compare the effectiveness of nirsevimab treatment in preventing RSV bronchiolitis in pediatric emergency departments during the first and second seasons of implementation of treatment in France.

DESIGN, SETTING, AND PARTICIPANTS: This a multicenter test-negative case-control study included 636 infants younger than 1 year who received a diagnosis of a first bronchiolitis episode in 5 pediatric emergency departments in France during the 2 first seasons of implementation of nirsevimab treatment (from October 5, 2023, to February 29, 2024, and from October 15, 2024, to January 31, 2025) and underwent a nasopharyngeal test for RSV.

MAIN OUTCOMES AND MEASURES: The main outcome of the study was the RSV status of the bronchiolitis cases. Multivariable logistic regression was performed with nirsevimab as the explanatory variable, adjusted on age, sex, risk factors of bronchiolitis, type of childcare, month, and center of inclusion. Effectiveness was calculated for each season and compared using the likelihood ratio test. Subgroup analysis by age and severity as well as sensitivity analyses were performed.

RESULTS: The study included 636 patients with bronchiolitis (median age, 3.0 months [IQR, 1.4-5.0 months]; 333 boys [52.4%]). In both seasons, 162 of 636 patients (25.5%) were immunized with nirsevimab. During the first season of implementation, 273 of 384 patients (71.1%) tested positive for RSV; during the second season, 181 of 252 patients (71.8%) tested positive for RSV. The effectiveness of nirsevimab treatment against RSV bronchiolitis was estimated to be 83.2% (95% CI, 68.0%-91.4%) during the first season and 89.3% (95% CI, 77.8%-95.1%) during the second season; no statistically significant difference in effectiveness was found between the 2 seasons (P = .97). Subgroup and sensitivity analyses provided similar results.

CONCLUSIONS AND RELEVANCE: In this test-negative case-control study of nirsevimab treatment, its effectiveness in reducing pediatric emergency department visits for RSV bronchiolitis during the second season of national immunization was high and comparable with that observed in the first season. Although RSV-B resistant strains had been recently identified, it did not appear to have important clinical consequences to date. Continued close monitoring of RSV epidemiology in the context of the widespread nirsevimab use remains essential.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Lenglart L, Levy C, Basmaci R, et al. Nirsevimab Treatment of RSV Bronchiolitis in Pediatric Emergency Departments. JAMA Netw Open. 2025. PMID: 41165704. doi:10.1001/jamanetworkopen.2025.40720

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。